

RESEARCH

Open Access



# Human intestinal organoid-derived PDGFR $\alpha$ + mesenchymal stroma enables proliferation and maintenance of LGR4 + epithelial stem cells

JunLong Chen<sup>1,2</sup>, Shinichiro Horiuchi<sup>3</sup>, So Kuramochi<sup>1</sup>, Tomoyuki Kawasaki<sup>1</sup>, Hayato Kawasumi<sup>1</sup>, Saeko Akiyama<sup>1,2</sup>, Tomoki Arai<sup>1</sup>, Kenichi Morinaga<sup>4</sup>, Tohru Kimura<sup>5</sup>, Tohru Kiyono<sup>6</sup>, Hidenori Akutsu<sup>1</sup>, Seiichi Ishida<sup>3,7</sup> and Akihiro Umezawa<sup>1,2\*</sup>

## Abstract

**Background** Intestinal epithelial cells derived from human pluripotent stem cells (hPSCs) are generally maintained and cultured as organoids in vitro because they do not exhibit adhesion when cultured. However, the three-dimensional structure of organoids makes their use in regenerative medicine and drug discovery difficult. Mesenchymal stromal cells are found near intestinal stem cells in vivo and provide trophic factors to regulate stem cell maintenance and proliferation, such as BMP inhibitors, WNT, and R-spondin. In this study, we aimed to use mesenchymal stromal cells isolated from hPSC-derived intestinal organoids to establish an in vitro culture system that enables stable proliferation and maintenance of hPSC-derived intestinal epithelial cells in adhesion culture.

**Methods** We established an isolation protocol for intestinal epithelial cells and mesenchymal stromal cells from hPSCs-derived intestinal organoids and a co-culture system for these cells. We then evaluated the intestinal epithelial cells and mesenchymal stromal cells' morphology, proliferative capacity, chromosomal stability, tumorigenicity, and gene expression profiles. We also evaluated the usefulness of the cells for pharmacokinetic and toxicity studies.

**Results** The proliferating intestinal epithelial cells exhibited a columnar form, microvilli and glycocalyx formation, cell polarity, and expression of drug-metabolizing enzymes and transporters. The intestinal epithelial cells also showed barrier function, transporter activity, and drug-metabolizing capacity. Notably, small intestinal epithelial stem cells cannot be cultured in adherent culture without mesenchymal stromal cells and cannot be replaced by other feeder cells. Organoid-derived mesenchymal stromal cells resemble the trophocytes essential for maintaining small intestinal epithelial stem cells and play a crucial role in adherent culture.

**Conclusions** The high proliferative expansion, productivity, and functionality of hPSC-derived intestinal epithelial cells may have potential applications in pharmacokinetic and toxicity studies and regenerative medicine.

**Keywords** Mesenchyme, Intestinal stem cells, Pluripotent stem cells, Organoids, Trophocytes, GREM1, Regeneration, Adherent culture, Epithelium-mesenchyme co-culture, Pharmacokinetics

\*Correspondence:

Akihiro Umezawa

umezawa@1985.jukuin.keio.ac.jp

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

The small intestine is the largest organ that facilitates the absorption of nutrients and conveys them to the bloodstream for distribution throughout the body. Intestinal epithelial cells contain a plethora of transporters and metabolic enzymes, including CYP3A4, which plays a pivotal role in the absorption and metabolic processing of drugs and is therefore a crucial enzyme in drug discovery. [1, 2] As such, it is imperative to assess the gastrointestinal tract's capacity for absorbing and metabolizing drugs during the drug discovery phase. The mainstream approach to drug discovery primarily involves the utilization of cells derived from experimental animals, Caco2 cells, and primary human cells, yet concerns remain regarding possible disparities in results owing to differences in species and gene expression between the epithelial cell models and human intestine [3, 4].

Pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, are pluripotent and immortal. Clinical applications include disease models and regenerative medicine; while, drug discovery applications include pharmacokinetic studies and organ-on-chip models. The advantage of pluripotent stem cells is that they can be used indefinitely by differentiating them into desired cell types *in vitro*, but complex induction protocols and the lack of passaging of differentiated cells are major challenges. Of particular concern are the lot-to-lot differences that occur when differentiating from pluripotent stem cells and when differentiated cells are repeatedly passaged and cryopreserved. During the process of proliferation in adherent culture, epithelial cells lose their morphology, barrier function, and metabolic capacity. In order to maintain their functionality, they must be cultured as three-dimensional structures called "organoids" [5–8]. These organoids are artificially fabricated to resemble living organs and are highly functional.

Two different fabrication methods are currently used for the production of organoids. For reconstructed organoids, parenchymal cells, stromal cells, and vascular endothelial cells are differentiated from pluripotent stem cells, mixed, and embedded in an extracellular matrix to create a three-dimensional organoid [5–8]. Self-organized organoids (self-organization) are generated based on the principles of embryonic development, in which different cell types organize in a highly coordinated manner to form complex structures such as organs [9]. Organoids can reproduce many of the characteristics and functions of the corresponding organs, such as the production of specific hormones or specific metabolic functions [5–9]. Self-organizing organoids are excellent models for studying organ development and disease because they better reproduce the natural cellular organization and structure of organs. They can also spontaneously generate a greater

variety of cell types, which may lead to a higher degree of complexity and functionality [9].

Intestinal epithelial stem and progenitor cells are influenced by subepithelial signals such as Wnt and BMPi (GREM1) [10–13]. Recent advances in high-resolution microscopy and single-cell RNA sequencing have revealed that subepithelial myofibroblasts [14–16], i.e., telocytes and trophocytes, are a source of mesenchymal trophic factors [17, 18]. These myofibroblasts in the mucosal layer perform a niche function: Co-culture with myofibroblasts contributes to the proliferation of intestinal organoids via Wnt, Rspo, and BMPi [12, 14]. These myofibroblasts are Vimentin<sup>+</sup>,  $\alpha$ -SMA<sup>+</sup> and Desmin<sup>-</sup>. Trophocytes, one type of myofibroblasts, are CD81<sup>+</sup> and PDGFRA<sup>low</sup>. [18]

Mesenchymal stromal cells play a crucial role in the maintenance of epithelium in many tissues and organs. Mesenchymal stromal cells can also facilitate the long-term culture of human hepatocytes through Wnt3a and R-spondin 1 [19]. This study highlights the utility of mesenchymal cells derived from intestinal organoids to support the growth and maintenance of human LGR4-positive intestinal stem cells.

## Materials and methods

### Culture of human iPSCs

Human iPSCs (EDOM22 #8) derived from menstrual blood were used [20, 21]. The iPSCs were cultured on dishes coated with vitronectin (A14700, Thermo Fisher Scientific) in Stem flex medium (A3349401, Thermo Fisher Scientific). The dishes were coated with 5  $\mu$ g/ml vitronectin at room temperature for 1 h. The medium was changed daily. The iPSCs were detached with 0.5 mM EDTA (06894–14, Nacalai tesque) for 5 min and passaged at 1100 cells/cm<sup>2</sup> every week.

### Culture of human ESCs

Human ESCs (SEES2) were cultured on dishes coated with iMatrix-511 silk (892,021, nippi) in StemFit medium (RCAK02N, Ajinomoto) [22, 23]. The dishes were coated with 1.7  $\mu$ g/ml iMatrix-511 silk at 37 °C for 1 h. The medium was changed daily. ESCs were detached with a 1:1 mixture of 0.5 mM EDTA and TrypLE™ Select (A1217701, Thermo Fisher Scientific) for 5 min and passaged at 550 cells/cm<sup>2</sup> every week.

### Generation of intestinal organoid

To generate intestinal organoids, ESCs or iPSC were dissociated using 0.5 mM EDTA or a 1:1 mixture of 0.5 mM EDTA and TrypLE™ Select and plated on a cell-patterning glass substrate CytoGraph (Dai Nippon Printing Co. Ltd.). CytoGraphs were coated with 5  $\mu$ g/ml vitronectin at room temperature for 30 min. The cells were cultured

in XF32 medium (81% Knockout DMEM (10,829,018, Thermo Fisher Scientific), 15% Knockout Serum Replacement XF CTS (12,618,013, Thermo Fisher Scientific), 2 mM GlutaMAX (35,050,061, Thermo Fisher Scientific), 0.1 mM NEAA (11,140,050, Thermo Fisher Scientific), Penicillin–Streptomycin (15,070,063, Thermo Fisher Scientific), 50 µg/ml L-ascorbic acid 2-phosphate (A8960, Sigma-Aldrich), 10 ng/ml heregulin-1β (080–09001, Fujifilm Wako Pure Chemicals Co., Ltd.), 200 ng/ml recombinant human IGF-1 (85580C, Sigma-Aldrich), and 20 ng/ml human bFGF (PHG0021, Thermo Fisher Scientific)). The first day of the passage was performed with medium containing Rho-associated protein kinase inhibitor Y-27632 (036–24023, Fujifilm Wako Pure Chemicals Co., Ltd.). Gut-like peristaltic organoids were collected at 40 to 60 days after the passage and transferred to 6-well Ultralow adhesion plates (3471, Corning).

#### Preparation of mouse embryonic fibroblasts

Mouse embryonic fibroblasts (MEF) were prepared for use as nutritional support (feeder) cells. Mouse fetuses were harvested after the parent mice were euthanized by cervical dislocation during inhalation anesthesia with 3% isoflurane. Heads, limbs, tails, and internal organs were removed from E12.5 ICR mouse fetuses (Japan CLEA), and the remaining torsos were then minced with a blade and seeded into culture dishes with DMEM (D6429, Sigma-Aldrich) supplemented with 10% FBS (10,091,148, Thermo Fisher Scientific) to allow cell growth. After 2 days of culture, the cells were passaged at a 1:4 ratio. After 5 days of culture, cells were trypsinized with 0.25% trypsin/1 mM EDTA (209–16941, Fujifilm Wako Pure Chemicals Co., Ltd.) and 1/100 (v/v) of 1 M HEPES buffer (15,630–106, Thermo Fisher Scientific) was added to the collected cells. Following irradiation with an X-ray apparatus (dose: 30 Gy, MBR-1520 R-3, Hitachi), the cells were cryopreserved with a TC protector (TCP-001DS, Pharma Biomedical, Osaka, Japan).

#### Preparation of intestinal stromal feeder cells (LONG)

Intestinal organoids were cut and spread on a 35-mm dish coated with iMatrix-511 silk. The dishes were coated with 1.7 µg/ml iMatrix-511 silk at 37 °C for 1 h. Then the attached fragments were cultured at 37 °C in 5% CO<sub>2</sub> with ESTEM-HE medium (GlycoTechnica). The medium was changed every 2 days. After 21 days of culture, the cells were trypsinized with 0.25% trypsin/1 mM EDTA for 3 min. The passage was onto a non-coated plate. The cells were cultured in XF32 medium at 0–3 days and then in ESTEM-HE medium at day 4 until just before passage. This passaging was performed at least three times, and the cells were purified before use for feeder cells. Thereafter, the medium was changed to DMEM supplemented

with 10% FBS at 37 °C in 5% CO<sub>2</sub>. The medium was changed every 3 days. The cells were passaged every 5–7 days and seeded at 3.6 × 10<sup>4</sup> cells/cm<sup>2</sup>. The cells were cryopreserved with STEM-CELLBANKER (ZR646, Nippon Zenyaku Kogyo Co., Ltd.) until use. The protocol for intestinal mesenchymal stromal cell production is shown in a flow chart (Additional file 1: Figure S1A).

#### Preparation of intestinal epithelial cells (RYU)

Intestinal organoids were cut and spread on 35-mm dishes coated with iMatrix-511 silk at 37 °C for 1 h. Dishes were coated with 1.7 µg/ml iMatrix-511 silk at 37 °C for 1 h. Then, fragments that had attached were cultured at 37 °C in 5% CO<sub>2</sub> with ESTEM-HE medium. The medium was changed every 2 days. After 28 days of culture, the cells were detached with 0.25% trypsin/1 mM EDTA and seeded onto confluent intestinal mesenchymal stromal cells. The cells were then cultured at 37 °C in 5% CO<sub>2</sub> in ESTEM-HE medium. The medium was changed every 2 days. The cells were passaged into 4–8 dishes after detachment with 0.25% trypsin/1 mM EDTA. The cells were cryopreserved with STEM-CELLBANKER. The procedure is shown in flow charts (Additional file 1: Figure S1A).

#### Preparation for histological studies

Samples were coagulated in iPCell (PG20-1, GenoStaff) following the manufacturer's instructions and fixed in 4% paraformaldehyde at 4 °C overnight. Fixed samples were embedded in a paraffin block to prepare thin cell sections. Deparaffinization, dehydration, and permeabilization were performed using standard techniques. Hematoxylin–eosin (HE) staining was performed with Carrazzi's hematoxylin solution (30,022, Muto Chemicals) and eosin Y (32,053, Muto Chemicals). Alcian blue staining was achieved with alcian blue solution pH2.5 (40,852, Muto Chemicals). Nuclei were counterstained with kernechtrot solution (40,872, Muto chemicals).

#### Immunostaining

Cells in culture (3910–035, IWAKI) were fixed with 4% paraformaldehyde for 15 min at room temperature. After washing with phosphate-buffered saline (PBS), cells were permeabilized with 0.25% Triton X-100 in PBS for 20 min, pre-incubated with Protein Block Serum-Free (X0909, Dako) for 30 min at room temperature and then exposed to primary antibodies overnight at 4 °C. After three washes with PBS, the cells were incubated with fluorescent secondary antibodies for 1 h at room temperature and washed three times with PBS. Nuclei were stained with a mounting medium containing 4',6-diamidino-2-phenylindole dihydrochloride solution (DAPI) (H-1200, Vector Laboratories).

For immunofluorescence staining of thin cell sections, deparaffinized cell sections were unmasked epitopes by heating with histophine (415,211, NICHIREI) in a microwave oven at a power setting of 700 W for 20 min. After three washes with PBS, sections were incubated with primary antibodies overnight at 4 °C. After three washes with PBS, the sections were incubated with secondary antibodies at room temperature for 30 min and washed three times with PBS. Nuclei were counterstained with a mounting medium containing DAPI (H-1800, Vector Laboratories).

When peroxidase-conjugated secondary antibodies were employed (424,154, NICHIREI), cell sections were exposed to 3% hydrogen peroxide/methanol for 5 min to block endogenous peroxidase and color development was performed with 3,3'-diaminobenzidine (4065-1, Muto Chemicals). The sections were counterstained with hematoxylin.

The antibodies listed in Tables 1 and 2 were diluted as indicated in PBS containing 1% BSA (126,575, Calbiochem).

**Table 1** Antibodies used for immunostaining

Antigen	Company	Cat. No	Dilution	Link
AE1/AE3	nichirei	412,811	1	<a href="https://www.nichirei.co.jp/bio/products/immunity/first_koutai.html">https://www.nichirei.co.jp/bio/products/immunity/first_koutai.html</a>
α-SMA	Sigma-Aldrich	A2547	1/400	<a href="https://www.sigmaaldrich.com/JP/ja/product/sigma/a2547">https://www.sigmaaldrich.com/JP/ja/product/sigma/a2547</a>
BCRP	Genetex	GTX100437	1/100	<a href="https://www.genetex.com/Product/Detail/ABCG2-antibody/GTX100437">https://www.genetex.com/Product/Detail/ABCG2-antibody/GTX100437</a>
CDH17	Sigma-Aldrich	HPA023614	1/100	<a href="https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa023614">https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa023614</a>
CDX2	Abcam	ab76541	1/100	<a href="https://www.abcam.co.jp/cdx2-antibody-epr2764y-ab76541.html">https://www.abcam.co.jp/cdx2-antibody-epr2764y-ab76541.html</a>
CES2	Abcam	ab126970	1/100	<a href="https://www.abcam.co.jp/ces2-antibody-ab126970.html">https://www.abcam.co.jp/ces2-antibody-ab126970.html</a>
Claudin-2	Invitrogen	51-6100	1/50	<a href="https://www.thermofisher.com/antibody/product/Claudin-2-Antibody-clone-MH44-Polyclonal/51-6100">https://www.thermofisher.com/antibody/product/Claudin-2-Antibody-clone-MH44-Polyclonal/51-6100</a>
Claudin-7	Invitrogen	34-9100	1/100	<a href="https://www.thermofisher.com/antibody/product/Claudin-7-Antibody-Polyclonal/34-9100">https://www.thermofisher.com/antibody/product/Claudin-7-Antibody-Polyclonal/34-9100</a>
CYP3A4	Abcam	ab135813	1/100	<a href="https://www.abcam.com/cytochrome-p450-3a4cyp3a4-antibody-ab135813.html">https://www.abcam.com/cytochrome-p450-3a4cyp3a4-antibody-ab135813.html</a>
Desmin	Dako	IS606	1	<a href="https://www.agilent.com/store/pt_BR/Prod-IS60630-2/IS60630-2">https://www.agilent.com/store/pt_BR/Prod-IS60630-2/IS60630-2</a>
E-Cadherin	BD biosciences	610,182	1/100	<a href="https://wwwbdbiosciences.com/en-us/products/reagents/microscopy-imaging-reagents/immunofluorescence-reagents/purified-mouse-anti-e-cadherin.610182">https://wwwbdbiosciences.com/en-us/products/reagents/microscopy-imaging-reagents/immunofluorescence-reagents/purified-mouse-anti-e-cadherin.610182</a>
Ki67	Dako	M7240	1/30	<a href="https://www.agilent.com/en-us/PageUnavailable?s=/www.agilent.com/ja-jp/product/immunohistochemistry/antibodies-controls/primary-antibodies/ki-67-antigen-(concentrate)-76646">https://www.agilent.com/en-us/PageUnavailable?s=/www.agilent.com/ja-jp/product/immunohistochemistry/antibodies-controls/primary-antibodies/ki-67-antigen-(concentrate)-76646</a>
MUC 2	Santa Cruz	SC-7314	1/50	<a href="https://www.scbt.com/p/mucin-2-antibody-ccp58">https://www.scbt.com/p/mucin-2-antibody-ccp58</a>
PEPT1	Sigma-Aldrich	HPA002827	1/50	<a href="https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa002827">https://www.sigmaaldrich.com/JP/ja/product/sigma/hpa002827</a>
P-gp	Abcam	ab170904	1/100	<a href="https://www.abcam.co.jp/p-glycoprotein-antibody-epr10364-57-ab170904.html">https://www.abcam.co.jp/p-glycoprotein-antibody-epr10364-57-ab170904.html</a>
SOX9	Millipore	AB5535	1/500	<a href="https://www.merckmillipore.com/JP/ja/product/Anti-Sox9-Antibody,MM_NF-AB5535">https://www.merckmillipore.com/JP/ja/product/Anti-Sox9-Antibody,MM_NF-AB5535</a>
Villin	Invitrogen	PA5-32,638	1/50	<a href="https://www.thermofisher.com/antibody/product/Villin-Antibody-Polyclonal/PA5-32638">https://www.thermofisher.com/antibody/product/Villin-Antibody-Polyclonal/PA5-32638</a>
Vimentin	Dako	M7020	1/100	<a href="https://www.agilent.com/en/product/immunohistochemistry/antibodies-controls/primary-antibodies/vimentin-(concentrate)-76509">https://www.agilent.com/en/product/immunohistochemistry/antibodies-controls/primary-antibodies/vimentin-(concentrate)-76509</a>
ZO-1	Invitrogen	61-7300	1/50	<a href="https://www.thermofisher.com/antibody/product/ZO-1-Antibody-Polyclonal/61-7300">https://www.thermofisher.com/antibody/product/ZO-1-Antibody-Polyclonal/61-7300</a>

**Table 2** Secondary antibodies used for immunostaining

Antibody	Company	Cat. No	Dilution	Link
Alexa Fluor 488 goat anti-Mouse IgG(H+L)	Invitrogen	A28175	1/500	<a href="https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG-H-L-Secondary-Antibody-Recombinant-Polyclonal/A28175">https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG-H-L-Secondary-Antibody-Recombinant-Polyclonal/A28175</a>
Alexa Fluor 488 goat anti-Mouse IgG2α	Invitrogen	A21131	1/500	<a href="https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG2a-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21131">https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG2a-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21131</a>
Alexa Fluor 488 goat anti-Rabbit IgG(H+L)	Invitrogen	A11008	1/500	<a href="https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11008">https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11008</a>
Alexa Fluor 546 goat anti-Mouse IgG(H+L)	Invitrogen	A11003	1/500	<a href="https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11003">https://www.thermofisher.com/antibody/product/Goat-anti-Mouse-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11003</a>
Alexa Fluor 546 goat anti-Rabbit IgG(H+L)	Invitrogen	A11010	1/500	<a href="https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11010">https://www.thermofisher.com/antibody/product/Goat-anti-Rabbit-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11010</a>

### Population Doubling

Cells were seeded from one 10-cm dish (353,003, Falcon) into four 10-cm dishes at each passage. Population doubling was estimated from passage number.

### Karyotypic analysis

Karyotypic analysis was contracted out to Nihon Gene Research Laboratories (Sendai, Japan). To assess diploidy, 50 cells at metaphase were examined. Metaphase spreads were prepared from cells treated with 100 ng/mL of Colcemid (KaryoMax, Gibco; Thermo Fisher Scientific, MA, USA) for 6 h. The cells were fixed with methanol: glacial acetic acid (2:5) three times and placed onto glass slides. Giemsa banding was applied to metaphase chromosomes. A minimum of 10 metaphase spreads were analyzed for each sample and karyotyped using a chromosome imaging analyzer system (Applied Spectral Imaging, CA, USA).

### Microarray analysis

Total RNA was isolated using miRNeasy mini kit (217,004, QIAGEN, Hilden, Germany). RNA samples were labeled and hybridized to a SurePrint G3 Human GEO microarray 8×60 K Ver 3.0 (Agilent, CA, USA), and the raw data were normalized using the 75-percentile shift. Gene expression profiles of hSI were analyzed using human small intestine total RNA (R1234226-50, biochain). Results were visualized with cluster maps and boxplots using the R package ggplot2 and ComplexHeatmap. The expression profile of this study was deposited in NCBI's Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE250634>).

### Quantitative RT-PCR analysis

The cultured cells were washed twice with Dulbecco's phosphate-buffered saline (Sigma-Aldrich, St Louis, MO, USA) before the isolation of total RNA. RNA extraction was carried out using the RNeasy total RNA extraction kit (QIAGEN, Hilden, Germany) as per the manufacturer's guidelines. To quantify the gene expression levels, qPCR was performed using 8 ng of total RNA, following reverse transcription with the High Capacity RNA-to-cDNA kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. The QuantStudio 7 Flex Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) was used to measure gene expression levels, and primers and probe sets were utilized

**Table 3** Primers used for qRT-PCR

Gene Symbol	Assay ID
CYP1A1	Hs01054797_g1
CYP1A2	Hs00167927_m1
CYP2B6	Hs04183483_g1
CYP2C9	Hs00426397_m1
CYP2C19	Hs00426380_m1
CYP2D6	Hs00164385_m1
CYP3A4	Hs00430021_m1
VDR	Hs00172113_m1
PXR	Hs00243666_m1
AHR	Hs00169233_m1
GR	Hs00230813_m1
P-gp	Hs00184500_m1
BCRP	Hs01053790_m1
PEPT1	Hs00192639_m1
OATP2B1	Hs01030343_m1
MRP2	HS00960489_m1
MRP3	Hs00978452_m1

to detect each gene transcript, as listed in Table 3. The expression levels of the genes are presented relative to RNAs derived from a human small intestine (R1234226-50, BioChain Institute, Inc., Newark, CA, USA).

### Cell transplantation

Male immunodeficient (NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic) mice, aged 6–8 weeks, (Charles River Laboratories, Inc., Wilmington, MA) were used in this study. The mice were anesthetized by inhalation of 3% isoflurane (099–06571, Fujifilm Wako Pure Chemicals Co., Ltd.). Under sterile conditions, a 1–2 cm incision was made below the ribs and 0.5 cm off-center but parallel to the spine. One kidney was gently pulled out and kept moist with sterile saline. A cell suspension was gently pulled into a 1 ml syringe with a 27G needle. The injection site was located at the upper or/and lateral side of the kidney to avoid damage to kidney blood vessels. The needle was slowly pushed into the capsule, as far as possible, toward the inferior pole of the kidney to avoid perforating the kidney capsule in other areas. The cells in 50 µL of medium were injected into the kidney capsule with a syringe, a sterile cotton swab was placed over the kidney capsule to prevent cell leakage, and the needle was slowly withdrawn. The kidney was put back into the body cavity using the sterile cotton swab without applying pressure to it. Finally, the abdominal wall was closed with a suture.

Following cell transplantation, the mice were housed individually. The kidneys were removed after mice were euthanized by cervical dislocation during inhalation anesthesia with 3% isoflurane. The mice that expired or were subjects of humanitarian euthanasia preceding the designated data acquisition time points were excluded from the analysis. The tally of excluded mice in this investigation amounted to zero. Our reporting of animal experiments adheres to the ARRIVE guidelines (<http://www.nc3rs.org.uk/page.asp?id=1357>).

#### Transmission electron microscopy (TEM) and scanning electron microscopy (SEM)

For transmission electron microscopy of cultured cells, cells were washed three times with PBS. Fixation was performed in PBS containing 2.5% glutaraldehyde for 2 h. The cells were embedded in epoxy resin. Ultrathin sections cut vertically to the culture surface were double stained in uranyl acetate and lead citrate and were viewed under a JEM-1200 PLUS transmission electron microscope (Nihon Denshi) and SU6600 (Hitachi High-Tech corporation).

#### Caco-2 Cell Culture

Caco-2 cells were purchased from ECACC (Lot: 12F018). Caco-2 cells were cultured DMEM supplemented with 10% FBS at 37 °C in 5% CO<sub>2</sub> for 14 days. The medium was changed every 2 days. The cells were seeded at 2.0 × 10<sup>5</sup> cells/cm<sup>2</sup>.

#### Trans-epithelial electrical resistance (TEER) measurements

The cells were seeded onto Transwell inserts (353,095, Falcon) and cultured until confluent. The Millicell-ERS (Electrical Resistance System) with chopstick electrodes was used to measure construct trans-epithelial electrical resistance (TEER). The instrument was calibrated with a 1000 Ω resistor prior to measurements, and an empty Transwell was used as a blank. Constructs were equilibrated to room temperature and switched to basal media for readings. The blank Transwell and all samples were measured three times. Samples and blanks were measured in triplicate, averaged, and used in the following calculations:

$$R_{\text{CELL}}(\Omega) = R_{\text{MEASURE}} - R_{\text{BLANK}}$$

$$\text{TEER} = R_{\text{CELL}}(\Omega) \times S_{\text{AREA}}(\text{cm}^2)$$

$$S_{\text{AREA}} = 0.3 \text{ cm}^2$$

#### Permeability and transport assay

The cells were seeded on Transwell inserts and cultured until confluent. Before the start of the assay, samples were pre-incubated with transport buffer (HBSS (14,025,092, Gibco) supplemented with 10 nM HEPES (15,630,106, Gibco) and 4.5 mg/ml glucose) for 1 h. Lucifer yellow solution (125–06281, Fujifilm Wako Pure Chemicals Co., Ltd.) was added to the apical side to a final concentration of 300 μM and then drawn out of the basal side at 30 min intervals for up to 120 min at 37 °C with shaking at 40 rpm. Rhodamine123 solution (187–01703, Fujifilm Wako Pure Chemicals Co., Ltd.) was added to the apical or basal side to a final concentration of 5 μM and then drawn out of the basal side at 60 min intervals for up to 120 min at 37 °C with shaking 40 rpm. An equal volume of transport buffer was immediately added to the drawn out side after each sampling. Lucifer yellow fluorescence was measured using a SYNERGY H1 microplate reader (Bio-Tek) at 428 nm excitation and 536 nm emission, and Rhodamine123 fluorescence was measured at 480 nm excitation and 530 nm emission. Papp was calculated using the following equation:

$$P_{\text{app}} = (1/A \times C_0) (dQ/dt)$$

where dQ/dt is the rate of drug permeation across the cell monolayer, C<sub>0</sub> is the donor-compartment concentration at time zero and A is the area of the cell monolayer. The ER was defined as Papp (basal-to-apical)/Papp (apical-to-basal).

#### Cytochrome P450 induction assays

Cells cultured in the 24-well plates in ESTEM-HE medium were treated with 100 nM vitaminD3 (D1530-10UG, Sigma-Aldrich) or 40 μM β-naphthoflavone (N3633-1G, Sigma-Aldrich) or 50 μM omeprazole (150–02091, Fujifilm Wako Pure Chemicals Co., Ltd.) for 24 h or 20 μM rifampicin (189–01001, Fujifilm Wako Pure Chemicals Co., Ltd.) or 500 μM phenobarbital (162–11,602, Fujifilm Wako Pure Chemicals Co., Ltd.) or 100 μM dexamethasone (194,561, MP Biomedicals, Illkirch, France) for 48 h at a cell density of 80%. Controls were treated with DMSO (final concentration 0.1%).

#### Determination of CYP3A4 activity

The cells were incubated with the assay buffer (HBSS supplemented with 10 nM HEPES and 4.5 mg/ml glucose) containing 50 μM testosterone (T1500, Sigma-Aldrich) at 37 °C for 2 h and the assay medium was withdrawn at 30, 60, 120 min. The cells were finally detached with 0.25%

trypsin/1 mM EDTA and collected for cell counting. The amount of the testosterone metabolite, 6 $\beta$ '-hydroxylated, was measured by LC–MS/MS (InertSustain<sup>®</sup> AQ-C18, LC-20A (SHIMADZU), API4000 (AB Sciex Pte. Ltd.)). The measurements were performed by Sumika Chemical Analysis Service, Ltd.

### The use of AI in writing

The authors wrote in their native language and generated the English text using AI, such as DeepL, ChatGPT-3.5, and Grammarly. Finally, We have asked an expert in life sciences to proofread the entire text in English.

## Results

### Intestinal epithelial cells can be isolated from organoids

Intestinal epithelial cells were generated from hPSC-derived self-organized intestinal organoids [9]. The organoids exhibited balloon-like structures 1 cm in diameter and were maintained as floating foam (Fig. 1A and B). Intestinal organoids had well-developed stromal cell layers and exhibited peristaltic-like movements, indicating highly functional small intestinal organoids (Fig. 1C). Intestinal organoids had a complex tissue structure, i.e., both epithelial and stromal cell layers (Fig. 1D and E). To collect intestinal epithelial cells, organoids were cut and processed into single sheets (Fragment, Fig. 1F). Then, the mesenchyme surface was adhered to a dish coated with laminin (Fig. 1G and H). On the first day, a minimum amount of medium was used to prevent intestinal organoid fragments from floating. The medium was returned to normal volume after confirming the adhesion of the intestinal organoids to the dish.

Mesenchymal stromal cells with a typical spindle shape started to migrate and proliferate from the adherent organoids within 7 days after the adhesion and covered the entire dish within 2 weeks (Fig. 1 I). The intestinal epithelial cells proliferated in the form

of colonies over 80% of the dish in 30 days (Fig. 1 I). The cells resembled fetal-derived intestinal epithelial cells in morphology (Fig. 1J) [24]. Interestingly, colonies of intestinal epithelial cells cultured in organoid production medium were maintained without cell proliferation for more than 60 days (data not shown). In addition, intestinal organoid-derived epithelial cells expressed CDX2 (Fig. 1K).


We employed a medium containing TGF- $\beta$  inhibitor, Cholera toxin, Nicotinamide, EGF, Noggin, Wnt3a and R-spondin1 that support the proliferative expansion of a diverse array of human epithelial cells [19, 25–28]. This study demonstrates that it is also efficacious for intestinal epithelial cells.

### Mesenchymal stromal cells support organoid-derived epithelial cells upon passage

We passaged the epithelial cells onto a mouse embryonic fibroblast (MEF) feeder. However, the epithelial cells failed to maintain their cell morphology and lost CDX2 expression at the center of the colonies (Figs. 2A, 2B and S2A). CDX2 expression was only observed at the periphery of the colonies, indicating that MEFs as a feeder are inappropriate for supporting intestinal epithelial cells. We then isolated mesenchymal stromal cells from intestinal organoids and examined their attributes. We defined "intestinal mesenchymal stromal cells" and "intestinal epithelial cells" isolated from intestinal organoids as "LONG" and "RYU", respectively, as code names. The mesenchymal stromal cells were positive for Vimentin and  $\alpha$ -SMA but negative for Desmin (Fig. 2C), showing a property of subepithelial myofibroblasts [14–16]. The mesenchymal stromal cells exhibited robust expression of trophocyte markers PDGFRA, CD81, and GREM1, while devoid of CD34 (Figs. 2D and 2E) [18, 29]. Mesenchymal stromal cells efficiently proliferated (Fig. 2F) but ceased to divide at passage 15, probably

(See figure on next page.)

**Fig. 1** Isolation of intestinal epithelial cells from small intestinal organoids **A** Macroscopic view of intestinal organoids. Bar: 10 mm. Inset: High-power view. Bar: 5 mm. **B** Phase-contrast micrograph of small intestinal organoids with submucosa. Scale bar: 500  $\mu$ m. **C** Phase-contrast photomicrographs of appropriate (left) and inappropriate (right) 'intestinal organoids'. Organ-derived small intestinal epithelium and mucosal stroma can be obtained from the appropriate organoids that have thick cell layers and low light transmission. Bar: 500  $\mu$ m. **D** Histology of small intestinal organoids with submucosa. HE stains. Scale bars: 200 (left), 50 (right)  $\mu$ m. **E** Schematic of small intestinal organoids with submucosa. **F** Phase-contrast micrographs of an organoid cut open and unfolded with scissors. Scale bars: 500  $\mu$ m. **G** Three-dimensional small intestinal organoids were bisected to expose the submucosa and attached to the dish. Cells were spread on the dish. **H** Macroscopic view of the dissected organoids that are attached to dishes. **I** Phase-contrast micrograph of a bisected organoid (black dotted lines) on 3, 13, 21, and 33 days after adhesion. Scale bars: 500  $\mu$ m. **J** Phase-contrast photomicrographs of proliferating intestinal epithelial cells on the mucosal stroma. Scale bar: 100  $\mu$ m. **K** Immunocytochemistry of adherent organoids with an antibody to CDX2, an intestinal epithelial marker. Nuclei were stained with 4',6-diamidino-2-phenylindole dihydrochloride solution (DAPI). Scale bars: 100  $\mu$ m



**Fig. 1** (See legend on previous page.)



due to replicative senescence (Additional file 2: Figure S2B). Mesenchymal stromal cells highly expressed RSPO3, BMP inhibitor (GREM1, FST), and WNT5A (non-canonical WNT) (Fig. 2G and H), which are key trophic factors in maintaining epithelial stemness [12, 18, 30].


We then investigated whether mesenchymal stromal cells support intestinal epithelial cell passaging. The intestinal epithelial cells maintained a typical columnar epithelial cell morphology with clear cell boundaries and formed colonies with CDX2-positive cells at 100% (Fig. 2I and J). Mesenchymal stromal cells as a feeder significantly rescued the decrease in CDX2 positive cells (Fig. 2I, J and Additional file 2: S2C). It is also noteworthy that mesenchymal stromal cells increased the adhesion of intestinal epithelial cells. Indeed, intestinal epithelial cells showed a low rate of adhesion to the dish in the absence of mesenchymal stromal cells, and the cells that did adhere showed a rapid loss of epithelial characteristics (Figure S3). Therefore, mesenchymal stromal cells play an essential role in maintaining characteristics and passaging intestinal epithelial cells, which previously could not be cultured in adherent culture. Likewise, mesenchymal stromal cells also supported intestinal spherical organoids using the standard established method (Figures Additional file 4: S4A and B) [7]. The establishment of mesenchymal stromal cells and intestinal epithelial cells is schematically illustrated (Fig. 2K and Additional file 1: S1A).

### Proliferation and genomic stability of epithelial cells on mesenchymal stromal cells

We investigated the proliferative capability of human embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC)-derived intestinal epithelial cells from 3D organoid technology (Fig. 3A and Additional file 1: S1B). A large number of mesenchymal stromal cells were cryopreserved for further use of feeder cells. Intestinal epithelial cells, after propagation on mesenchymal stromal cells, can easily be passaged, cryopreserved, and thawed. The intestinal epithelial cells were passaged from one to four dishes every 5–7 days (Fig. 3B and Additional file 8: Supplemental video). A marker for proliferating cells, Ki67, was detected in intestinal epithelial cells (Fig. 3C). Intestinal epithelial cells continued to proliferate until 30 population doublings, i.e.,  $2^{30}$  cells from 1 cell, in 120 days and stopped dividing (Fig. 3D–H). The intestinal epithelial cells lacked expression of the stem cell marker LGR5 but highly expressed LGR4, CD24, CD44, ZNF277, and SOX9 (Additional file 5: Figures S5A, S5B and S5C). Hence, the intestinal epithelial cells correspond to transient amplifying cells in the crypt base, but not intestinal stem cells [24, 31–33]. Intestinal epithelial cells showed a normal karyotype with high chromosomal stability (Fig. 3I). Intestinal epithelial cells and mesenchymal stromal cells formed a typical luminal structure with epithelial cells and stromal cells at the subrenal capsules of immunodeficient (NOD. Cg-Prkdcscid112rgtm1Sug/Shi<sup>J</sup>) mice [34]. Moreover, there was no evidence of tumorigenicity for either of the cell types (Figs. 3J and Additional file 5: S5D).

(See figure on next page.)

**Fig. 2** Serial culture of epithelial cells derived from small intestinal organoids **A** Phase-contrast micrograph of intestinal epithelial cells at passage 2 on mouse embryonic fibroblasts (MEF) (left) and immunohistochemistry of intestinal epithelial cells with an antibody to CDX2 (right). Immunohistochemistry was performed on cells in iPCell. Scale bars: 200 (left) and 50 (right)  $\mu\text{m}$ . **B** Immunocytochemistry of intestinal epithelial cells at passage 2 on MEF with an antibody to CDX2. Nuclei were stained with DAPI. Scale bar: 100  $\mu\text{m}$ . **C** Phase-contrast micrograph of and immunohistochemistry of mesenchymal stromal cells. Mesenchymal stromal cells exhibit spindle-shaped morphology. Mesenchymal stromal cells were positive for Vimentin and  $\alpha$ -SMA, but negative for Desmin. Nuclei were stained with DAPI. Scale bars: 100 (white) and 50 (yellow)  $\mu\text{m}$ . **D** Expression heat map of gene expression in intestinal epithelial cells and mesenchymal stromal cells. **E** Immunocytochemistry of mesenchymal stromal cells. Mesenchymal stromal cells were positive for trophocyte markers PDGFRA and CD81. Nuclei were stained with DAPI. Scale bar: 50  $\mu\text{m}$ . **F** Phase-contrast micrograph mesenchymal stromal cells. Days after a passage are shown. Scale bars: 200  $\mu\text{m}$ . **G** Trophic factor gene expression of intestinal epithelial cells and mesenchymal stromal cells. **H** Boxplot of representative Rspo, WNT, and BMP inhibitor families. Expression levels were calculated from the results of independent (biological) triplicate experiments (intestinal epithelial cells and mesenchymal stromal cells) and single experiments (normal adult intestine tissue). Boxplots are expressed as mean  $\pm$  SD. **I** Phase-contrast micrograph and immunohistochemistry of intestinal epithelial cells on organoid-derived mesenchymal stromal cells with an antibody to CDX2. Immunohistochemistry was performed on cells in iPCell. Scale bars: 200 (left) and 50 (right)  $\mu\text{m}$ . **J** Immunocytochemistry of intestinal epithelial cells on organoid-derived mesenchymal stromal cells with an antibody to CDX2. Nuclei were stained with DAPI. Scale bars: 100  $\mu\text{m}$ . **K** Schematic of successful maintenance and culture of intestinal epithelial cells on organoid-derived mesenchymal stromal cells. Epithelial cells and mesenchymal stromal cells were derived from the same organoids



**Fig. 2** (See legend on previous page.)

### Intestinal epithelial cells exhibit polarization in adherent culture

Immunostaining and scanning electron microscopy analysis revealed that intestinal epithelial cells are on top of the mesenchymal stromal cells (Fig. 4A and B). The structure of these cells in the adhesion culture resembled the epithelial mucosal layer of the small intestine and intestinal organoid. Histological analysis revealed that the intestinal epithelial cells had a typical columnar shape and formed villus structures (Fig. 4C). The epithelial cells were positive for CDX2 and epithelial keratins (AE1/3), and mesenchymal stromal cells were positive for Vimentin. The intestinal epithelial cells expressed Villin and transporters (BCRP, PEPT1, and P-gp) on the apical membrane side, indicating cell polarity (Fig. 4D). The intestinal epithelial cells produced acid mucus in the apical membrane and intracellular vacuoles (Fig. 4E). The vacuoles were positive for MUC2, specific for goblet cells in the small intestine (Fig. 4F). Electron microscopy analysis clearly revealed microvilli lined with actin filaments and a glycocalyx on the apical membrane (Figs. 4G and 4H). Intestinal epithelial cells are composed of absorptive enterocytes and goblet cells on two or more-layered mesenchymal stromal cells and show cell polarity (Fig. 4I).

### The intestinal epithelial cells have barrier function and P-gp ability


The intestinal tract serves as a selectively permeable barrier, which regulates the absorption of both nutrients and xenobiotics. Intestinal epithelial cells' barrier function and capacity to transport P-glycoprotein were quantified. The intestinal epithelial cells on mesenchymal stromal cells exhibited positivity for ECAD and CDH17, which are elements of adherens junctions. Likewise, the cells were positive for ZO-1, Claudin-2 and Claudin-7,

constituents of tight junctions (Fig. 5A). Transmission electron microscopy analysis revealed tight junctions and adherens junctions at the lateral membranes of the intestinal epithelial cells (Fig. 5B). We then evaluated the barrier function of the intestinal epithelial cells by trans-epithelial electrical resistance (TEER) measurements and Lucifer yellow (LY) assays (Figs. 5C and D). The TEER value for the intestinal epithelial cells on mesenchymal stromal cells was 235–311  $\Omega$  cm<sup>2</sup> (Fig. 5C). The Lucifer yellow apparent permeability (Papp) value was 0.45–0.98  $\times 10^{-6}$  cm/s for the intestinal epithelial cells on mesenchymal stromal cells (Fig. 5D). These results demonstrate that the intestinal epithelial cells possess a highly functional barrier function comparable or superior to Caco-2 cells. Subsequently, we examined the time course of intestinal epithelial cells' barrier function for 20 days (Fig. 5E). The intestinal epithelial cells on mesenchymal stromal cells demonstrated a consistent barrier function (Papp value: 1.5–2.6  $\times 10^{-6}$  cm/s) throughout the 20 days.

The intestinal epithelial cells and Caco-2 cells exhibit barrier function. We then confirmed the expression levels of intestinal transporters and examined their functionality. P-glycoprotein (P-gp) plays a crucial role in the intestinal absorption and excretion of drugs [35]. The intestinal epithelial cells express comparable levels of P-gp than Caco-2 cells and cryopreserved human enterocytes (Fig. 5F). We performed a transport assay using Rhodamine123 (P-gp substrate) in the intestinal epithelial cells (Fig. 5G). The intestinal epithelial cells on mesenchymal stromal cells exhibited asymmetric permeability of P-gp substrate Rhodamine123, with efflux ratios (ER) 6.7–21.1. Mesenchymal stromal cells exhibited an efflux ratio (ER) ranging from 0.6 to 0.7, which, in conjunction with the gene expression findings, indicates their

(See figure on next page.)

**Fig. 3** Extensive proliferation of organoid-derived intestinal epithelial cells on a stromal cell feeder layer **A** Schematic of organoid-derived intestinal epithelial cell culture system. Intestinal epithelial and mesenchymal stromal cells can be cultured, passaged and frozen, allowing for large stocks of cells. Intestinal epithelial and mesenchymal stromal cells are designated as RYU and LONG, respectively, as code names. **B** Phase-contrast micrographs of RYU growing on LONG. RYU formed colonies and proliferated. Scale bars: 100  $\mu$ m. **C** Immunocytochemistry of RYU P6 on a dish with the proliferating cell marker Ki67 and the epithelial cell-specific cadherin (ECAD (E-Cadherin/Cadherin-1/CD324)). Nuclei were stained with DAPI. Scale bar: 50  $\mu$ m. **D** Growth curve of RYU. Each point indicates the timing of passages. RYU were passaged into 4 dishes at each passage. **E** Histology and immunohistochemistry of RYU at passage 4 in iPCell. Immunohistochemistry was performed with antibodies to CDX2 and Villin. Scale bars: 50  $\mu$ m. **F** Histology and immunohistochemistry of RYU at passage 6 in iPCell. Immunohistochemistry was performed with antibodies to CDX2 and Villin. Scale bars: 50  $\mu$ m. **G** Histology and immunohistochemistry of RYU at passage 9 in iPCell. Immunohistochemistry was performed with antibodies to CDX2 and Villin. Scale bars: 50  $\mu$ m. **H** Histology and immunohistochemistry of RYU at passage 12 in iPCell. Immunohistochemistry was performed with antibodies to CDX2 and Villin. Scale bars: 50  $\mu$ m. **I** Karyotypic analysis revealed that RYU at passage 13 have normal karyotypes. **J** Immunohistochemistry of RYU and LONG at the subrenal capsule of the kidney ( $n=3$ , respectively), using human-specific Lamin A/C antibody. Scale bars of zoomed sections represent 100  $\mu$ m



**Fig. 3** (See legend on previous page.)

non-P-gp activity. These results suggest that the intestinal epithelial cells possess high P-gp activity comparable or superior to Caco-2 cells. The intestinal epithelial cells expressed other transporters, BCRP, PEPT1, OATP2B1, and MRP3; whereas, the expression of MRP2 was limited. (Fig. 5H). The expression of transporters except MRP2 was comparable to or superior to cryopreserved human enterocytes (IVAL-E1, E2, and E3).

#### Cytochrome P450 is induced in the intestinal epithelium by drugs

Of the cytochrome P450 enzymes (CYPs), CYP3A4 is the dominant drug-metabolizing enzyme [36]; and in the epithelial cells of the small intestine, carboxylesterase 2 (CES2) also metabolizes oral drugs possessing an ester structure [37, 38]. However, the expression levels of CES2 and CYP3A4 in Caco-2 cells are significantly lower than those observed in the human adult small intestine [39]. We evaluated the CYP gene expression and function in the intestinal epithelial cells. The intestinal epithelial cells expressed CYP1A1, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, but not CYP1A2 (Fig. 6A). The expression of CYPs was comparable to or higher than that in Caco-2 cells. The intestinal epithelial cells possessed the same level of CYP3A4 expression as cryopreserved human enterocytes. The intestinal epithelial cells exhibited distinct expression patterns when compared to CYP-expressing hepatocytes (Additional file 6: Figure S6A and S6B). Furthermore, the expression of CYPs in intestinal epithelium is induced by drugs [40, 41]. In the current study, we sought to examine CYP induction of intestinal epithelial cells. The intestinal epithelial cells grown on mesenchymal stromal cells exhibited induction of CYPs with exposure to Omeprazole (OM),  $\beta$ -Naphthoflavone (BNF), Phenobarbital (PB), Rifampicin (Rif), vitamin D (VD3), and Dexamethasone (Dex) through a wide range of nuclear receptors, i.e., PXR,


VDR, GR, and AHR (Fig. 6B and Additional file 6: S6C) [42, 43]. Furthermore, the intestinal epithelial cells were deficient in expression of the nuclear receptor CAR, similar to intestinal organoids [44]. The intestinal epithelial cells on mesenchymal stromal cells exhibited inhibition of CYP3A4 with exposure to Ketoconazole (Ket) (Additional file 6: Figure S6D). The intestinal epithelial cells were positive for CYP3A4 and CES2 (Fig. 6C). To evaluate CYP3A4 activity, the intestinal epithelial cells were incubated with testosterone, and the formation of 6 $\beta$ -hydroxytestosterone, a metabolite produced from testosterone by CYP3A4, was measured. CYP3A4 metabolic activity levels of the intestinal epithelial cells were 22–34-fold higher than those of Caco-2 cells (Fig. 6D and Additional file 6: S6E).

#### Puromycin-based selection of intestinal epithelial cells

We then aimed to validate the impact of mesenchymal stromal cells by eradicating these cells through the use of a cytotoxic antibiotic, puromycin [19, 27]. Puromycin is capable of preferentially selecting cells that possess drug-metabolizing enzymes while allowing for the survival of only intestinal epithelial cells (Additional file 7: Figure S7A and B). After puromycin selection, the intestinal epithelial cells continued to exhibit positivity for ECAD, CDH17, ZO-1, Claudin-2 and Claudin-7, which are elements of adherens and tight junctions. We then evaluated the barrier function of the puromycin-treated intestinal epithelial cells by TEER measurements and Lucifer yellow assays (Additional file 7: Figure S7D and E). The TEER value for the intestinal epithelial cells was 195–236  $\Omega$  cm<sup>2</sup> (Additional file 7: Figure S7D). The Lucifer yellow Papp value was 0.67–1.41  $\times 10^{-6}$  cm/s (Additional file 7: Figure S7E). These results demonstrate that the barrier function of intestinal epithelial cells is increased by placing intestinal epithelial cells on mesenchymal stromal feeders (Fig. 5C, D, Additional file 7: S7D and S7E).

(See figure on next page.)

**Fig. 4** Organoid-derived intestinal epithelial cells have polarity **A** Immunocytochemistry of RYU on LONG with the antibody to Vimentin and CDX2. RYU and LONG are positive for CDX2 and Vimentin, respectively. Scale bar: 100  $\mu$ m. **B** Transmission electron microscopic analysis of RYU on LONG. Adhesion between RYU and LONG was observed. Scale bars: 1000 (left) and 500 nm. **C** Histology and immunohistochemistry of RYU in iPCell. Immunohistochemistry was performed with antibodies to CDX2, AE1/AE3, and Vimentin. Scale bars: 50  $\mu$ m. **D** Immunohistochemistry of RYU in iPCell was performed with antibodies to Villin, BCRP, P-gp, and PEPT1. Strongly stained areas are indicated by black arrows. Scale bars: 50  $\mu$ m. **E** Alcian Blue stain of RYU in iPCell. Scale bars: 50 and 20 (inset)  $\mu$ m. **F** Immunohistochemistry of RYU in iPCell with antibodies to MUC2. Scale bar: 50  $\mu$ m. **G** Transmission electron microscopic analysis of epithelial apical membrane side. Microvilli and glycocalyx (yellow squares) were observed. Scale bar: 200 nm. **H** Scanning electron microscopic analysis of RYU on LONG. Microvilli were observed over the surface of RYU. Scale bar: 500 nm. **I** Schematic of RYU on LONG. RYU are polarized in adherent culture. The apical and basal sides of RYU are in contact with culture medium and LONG, respectively



**Fig. 4** (See legend on previous page.)

Subsequently, we followed a time course of intestinal epithelial cells' barrier function for 20 days (Figure S7E, S7G and S7H). Surprisingly, the puromycin-treated intestinal epithelial cells exhibited an unstable barrier function (Papp value: 2.3–6.0). We also performed a transport assay using Rhodamine123 in the puromycin-treated intestinal epithelial cells (Additional file 7: Figure S7I). The puromycin-treated intestinal epithelial cells demonstrated asymmetric permeability, with efflux ratios (ER) 5.9–18.1. The puromycin-treated intestinal epithelial cells expressed transporters, P-gp, BCRP, PEPT1, OATP2B1, and MRP3; whereas, the expression of MRP2 was limited (Fig. 5H and Additional file 7: S7J). These results suggest that mesenchymal stromal cells are required for long-term maintenance of intestinal epithelial cells.

## Discussion

This study shows that mesenchymal stromal cells derived from intestinal organoids play an important role in the proliferation and maintenance of intestinal epithelial cells in adherent cultures. This culture system is a readily available and potentially valuable model for examining the niche environment such as the extracellular matrix and cytokines provided by mesenchymal cells. Organoid-derived mesenchymal stromal cells contribute to the early maturation and maintenance of the function of intestinal epithelial cells.


Intestinal organoids derived from LGR5+ stem cells require the presence of EGF, Noggin to counteract BMP

signaling, as well as R-Spondin, a WNT agonist, and Wnt for maintenance [7]. Mesenchymal stromal cells located in the intestinal mucosa exert a stimulatory effect on the intestinal epithelium [12, 45–47]. The contribution of mesenchymal stromal cells is a multifactorial process, not attributable to a single element, and mediated through the secretion of soluble factors and the provision of scaffolds. Epithelial cells are modulated by a concentration gradient of trophic factors, namely WNT and BMP signaling. WNT, R-Spondin, and BMP inhibitors are highly concentrated at the base of the crypts, where small intestinal stem cells reside; while, the levels of these trophic factors decrease as the cells ascend to the villi [45, 48, 49]. Ultimately, the predominance of the BMP ligand determines the fate of the cells. PDGFRA+ and CD81+ stromal cells (trophocytes) around the crypts produce a BMP inhibitor, GREM1. Mesenchymal stromal cells derived from intestinal organoids in the present study may contribute to intestinal epithelial cell proliferation through soluble factors such as BMP inhibitor GREM1 [18]. The mesenchymal stromal cells appear to be trophocytes, as they produce GREM1, an important component of the stem cell niche.

Intestinal epithelial stem cells are located at the base of the crypts. Intestinal stem cells exhibit specific markers such as LGR4+ and LGR5+, and LGR5 expression is lost upon differentiation [33]. Enterocytes and goblet cells in the intestinal epithelial cell population probably suggest the presence of intestinal epithelial stem cells.

(See figure on next page.)

**Fig. 5** Barrier performance and transport capability of intestinal epithelial cells **A** Phase-contrast micrograph and immunocytochemistry of RYU on LONG. Immunocytochemistry was performed with antibodies to proteins with barrier functions (ECAD, CDH17, ZO-1, Claudin-2, Claudin-7) and CDX2. Nuclei were stained with DAPI. Scale bars: 500 (black) and 50 (yellow)  $\mu$ m. **B** Transmission electron microscopic analysis of epithelial lateral membrane. Tight junction (TJ) and adherens junction (AJ, white arrows) were observed. Scale bar: 500 nm. **C** Trans-epithelial electrical resistance measurements of Caco-2, LONG, and intestinal epithelial cells derived from human iPSCs (iPSC-RYU) and ESCs (ESC-RYU) on LONG. LONG and Caco-2 cells served as negative and positive controls, respectively. Results are expressed as mean  $\pm$  SD ( $n=3$  triplicate biological experiments). Statistical significance was determined using Dunnett's test. **D** Lucifer Yellow permeability test of iPSC-RYU and ESC-RYU on LONG. Caco-2 and LONG were prepared as controls. Results are expressed as mean  $\pm$  SD ( $n=3$  triplicate biological experiments). Statistical significance was determined using Dunnett's test. **E** Lucifer Yellow permeability test was performed for barrier performance. Barrier performance of RYU on LONG. Results are expressed as mean  $\pm$  SD ( $n=3$  triplicate biological experiments). **F** P-glycoprotein (P-gp) gene expression by qRT-PCR analysis in iPSC-RYU and ESC-RYU on LONG in a Transwell. Caco-2 cells and cryopreserved human enterocytes served as controls. The expression level of adult small intestine whole tissue was set to 1.0. Results are expressed as mean  $\pm$  SD ( $n=3$  triplicate biological experiments). **G** Permeability test with Rhodamine 123. The efflux ratio (ER) for Rhodamine 123 was derived from the Papp values associated with basal-to-apical transport (B to A) and apical-to-basal transport (A to B). iPSC-RYU and ESC-RYU on LONG. Mesenchymal stromal cells alone (ESC-LONG and iPSC-LONG) and Caco-2 cells served as negative and positive controls, respectively. Results are expressed as mean  $\pm$  SD ( $n=3$  triplicate biological experiments). Statistical significance was determined using Student's t-test. **H** Expression of the genes for transporters (BCRP, PEPT1, OATP2B1, MRP2, and MRP3). The expression level of adult small intestine whole tissue was set to 1.0. Expression levels were calculated from the results of independent (biological) triplicate experiments. Results are expressed as mean  $\pm$  SD ( $n=3$ ). ES-RYU: human ESC-derived intestinal epithelial cells, iPS-RYU: human iPSC-derived intestinal epithelial cells



**Fig. 5** (See legend on previous page.)



High expression of LGR4 and a lack of LGR5 indicate that the intestinal epithelium with proliferative capacity and multipotency correspond to transient amplifying progenitor cells (TA cells). The CD24<sup>+</sup>/CD44<sup>+</sup> intestinal epithelial cells in this study can be consistent with the LGR5-negative multipotent cell population at the base of the intestinal crypts [31, 32]. Intense Wnt signal-dependent multipotency and proliferation of TA cells may explain the strong proliferative potential of the organoid-derived intestinal epithelial cells (RYU) generated in this study [31, 50, 51].

The intestinal epithelial cells on mesenchymal feeders possess barrier ability and can be applied in developing an absorption-accelerating agent. Caco-2 cells lack a mucosal layer [52]; whereas, pluripotent stem cell-derived intestinal epithelial cells have goblet cells and form a mucosal layer. Comparable barrier function and expression of P-gp and CYPs in the organoid-derived epithelial cells (RYU) with frozen human intestines suggest that the organoid-derived epithelial cells can contribute to drug development and pharmacokinetics. Furthermore, high expression of AHR, PXR, VDR, and GR and the induction of CYPs by the drugs through these receptors may lead to the availability of the cells as an in vitro simulator for drug-drug interactions [40]. The inducibility of CYP3A by rifampicin has been documented in human intestinal enterocytes; whereas, Caco-2 cells exhibit no such inducibility [53]. The development of an accurate and reproducible differentiation method can contribute to the evaluation of intestinal absorption of drugs in humans. Because of the limited availability of cell types enabling the concurrent assessment of metabolic enzymes, transporters, and mucosal layers, intestinal

epithelial cells can be a compelling model for evaluating the pharmacokinetics of the human small intestine. Moreover, the intestinal epithelial cells have the potential to reflect enterocyte functionality more accurately than Caco-2 cells.


By our calculations, intestinal epithelial cells can proliferate at least up to  $1 \times 10^{10}$ . Intestinal epithelial cells can form cell sheets and possibly contribute to the improvement of esophageal stricture as well as oral mucosal epithelial cells [54]. Likewise, the cell sheets of intestinal epithelial cells improve inflammatory bowel diseases such as Crohn's disease [55]. Mesenchymal stromal cells in the sheets may mitigate inflammation through immune tolerance and anti-inflammatory cytokines like marrow stromal cells and adipocytes [56].

### Conclusion

This study shows that mesenchymal stromal cells from self-assembled intestinal organoids generate functional enterocytes and LGR4-positive functional intestinal epithelial stem cells in two-dimensional culture. The combination of these epithelial stem cells and mesenchymal stromal cells achieves epithelial multipotency, precise lineage control by the stroma, a niche environment provided by the stroma, and self-organization of the epithelium. It also demonstrates the potential for building a robust platform for drug discovery and toxicology to study the effects of environmental pollutants, chemicals, and pharmaceuticals on humans. Furthermore, their proliferation rate, which is several orders of magnitude faster than organoids, has potential applications in regenerative medicine, preclinical studies, and disease models.

(See figure on next page.)

**Fig. 6** Induction of the genes for cytochrome P450 in organoid-derived epithelial cells (A) Expression of the genes for cytochrome P450 (CYP1A1, CYP2B6, CYP2D6, CYP3A4, CYP2C9, and CYP2C19). The expression levels of adult small intestine whole tissue were set to 1.0. Expression levels were calculated from the results of independent (biological) triplicate experiments. Results are expressed as mean  $\pm$  SD ( $n = 3$ ). ES-LONG: human ESC-derived mesenchymal stromal cells, ES-RYU: human ESC-derived intestinal epithelial cells, iPS-LONG: human iPSC-derived mesenchymal stromal cells, iPS-RYU: human iPSC-derived intestinal epithelial cells. (B) Induction of the cytochrome P450 genes with exposure to Omeprazole (OM),  $\beta$ -Naphthoflavone (BNF), Phenobarbital (PB), Rifampicin (Rif), vitamin D (VD3), and Dexamethasone (Dex). Results are expressed as mean  $\pm$  SD ( $n = 3$ ). The expression level of each gene without any treatment (DMSO) was set to 1.0. Expression levels were calculated from the results of independent (biological) triplicate experiments. Statistical significance was determined using Student's t-test; \*\* Fold  $> 2$ ,  $p < 0.01$ , \* Fold  $> 2$ ,  $p < 0.05$ . (C) Immunocytochemistry of RYU with antibodies to CYP3A4 and CES2, which are drug-metabolizing enzymes. Nuclei were stained with DAPI. Scale bars: 50  $\mu$ m. (D) Measurement of CYP3A4 activity. The levels of 6 $\beta$ -hydroxy testosterone were measured. Results are expressed as mean  $\pm$  SD ( $n = 3$  triplicate biological experiments). Statistical significance was determined using Dunnett's test



**Fig. 6** (See legend on previous page.)

## Abbreviations

hPSC	Human pluripotent stem cells
BMPi	BMP inhibitor
MEF	Mouse embryonic fibroblasts
RYU	Intestinal epithelial cells derived from intestinal organoids
LONG	Intestinal mesenchymal stromal cells derived from intestinal organoids
ESC	Embryonic stem cells
iPSC	Induced pluripotent stem cells
PD	Population doubling
TEER	Trans-epithelial electrical resistance
Papp	Apparent permeability
ER	Efflux ratio
OM	Omeprazole
BNF	$\beta$ -Naphthoflavone
PB	Phenobarbital
Rif	Rifampicin
VD3	Vitamin D <sub>3</sub>
Dex	Dexamethasone
Ket	Ketoconazole
6 $\beta$ -OHT	6 $\beta$ -Hydroxytestosterone
TA cells	Transient amplifying progenitor cells
TEM	Transmission electron microscopy
SEM	Scanning electron microscopy

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13287-023-03629-5>.

**Additional file1:** Generation of intestinal epithelial and mesenchymal stromal cells from intestinal organoids (A) Experimental scheme for generation of the intestinal epithelial and mesenchymal stromal cells from small intestinal organoids. Intestinal epithelial cells and mesenchymal stromal cells were isolated at 21 and 28 days, respectively. (B) Details of intestinal epithelial and mesenchymal stromal cells established from human iPSC- and ESC-derived intestinal organoids.

**Additional file2:** Mesenchymal stromal cells supported intestinal epithelial cells (A) Histology and immunohistochemistry of RYU on MEFs. Immunohistochemistry was performed with antibodies to CDX2, Villin, and AE1/AE3. Scale bars: 200  $\mu$ m (upper panels), 50  $\mu$ m (lower panels). (B) Phase-contrast photomicrographs of LONG at Passages 5, 10, and 15. LONG ceased their proliferation at Passage 15. Scale bars: 500  $\mu$ m. (C) Histology and immunohistochemistry of RYU on LONG. Scale bars: 200  $\mu$ m (upper panels), 50  $\mu$ m (lower panels).

**Additional file3:** Intestinal epithelial cells require mesenchymal stromal cells (A) Phase-contrast photomicrograph (left-upper) and histology (the others) of RYU on RYU. (Right-upper) H.E. stain. (Lower) Immunohistochemistry of RYU with antibodies to CDX2 (left-lower) and Villin (right-lower). Scale bars: 500  $\mu$ m (left-upper) and 50  $\mu$ m (the others). (B) Phase-contrast photomicrograph (left-upper) and histology (the others) of RYU on the non-coated dish. (Right-upper) H.E. stain. (Lower) Immunohistochemistry of RYU with antibodies to CDX2 (left-lower) and Villin (right-lower). Scale bars: 500  $\mu$ m (left-upper) and 50  $\mu$ m (the others). (C) Relative adhesion efficiency of RYU on LONG or no feeder. The number of colonies for RYU cultured on LONG was set to 1.0. RYU cultured on LONG resulted in 392 colonies. RYU cultured on no feeder yielded 23 colonies. (D) Phase-contrast photomicrograph (left-upper) and histology (the others) of RYU on the extracellular matrix-coated dish (Matrigel, Collagen type-I, IV, Laminin-511 and 521). (Right-upper) H.E. stain. (Lower) Immunohistochemistry of RYU with antibodies to CDX2 (left-lower) and Villin (right-lower). Scale bars: 500  $\mu$ m (left-upper) and 50  $\mu$ m (the others).

**Additional file4:** Mesenchymal stromal cells promote proliferation of the intestinal epithelial cell organoids (A) Phase-contrast photomicrographs of intestinal epithelial cell (RYU) organoids on mesenchymal stromal cells (LONG) at days 6, 8, and 11 in Matrigel. Left: Intestinal epithelial cell organoids on LONG. Right: Intestinal epithelial cell organoids alone (no feeder cells). Scale bars: 500  $\mu$ m. (B) Phase-contrast photomicrographs of

co-culture of intestinal epithelial cell organoids and LONG on LONG at day 6, 8, and 11 in Matrigel. Left: co-culture on LONG. Right: co-culture alone (no feeder cells). Scale bars: 500  $\mu$ m. (C) The area of individual intestinal epithelial cell organoids under distinct culture conditions on days 6, 8, and 11. N/A: not available (Organoid boundaries are blurred). Co-culture: RYU and LONG organoids. Feeder: feeder cells (LONG). (D) The area of intestinal epithelial cell organoids under distinct culture conditions on days 6, 8, and 11. Co-culture: RYU and LONG organoids. Feeder: feeder cells (LONG).

**Additional file5:** Intestinal epithelial cells are positive for crypt base cell (CBC) markers such as LGR4, CD24, and CD44 (A) Immunohistochemistry of RYU in iPCell (upper panel) and human small intestine tissue (lower panel) with antibodies to SOX9. Scale bars: 50  $\mu$ m. (B) Expression heat map of gene expression in RYU and LONG. n = 3 triplicate biological experiments. (C) Boxplot of representative human intestinal epithelial stem cells and differentiated cell markers. n = 3 triplicate biological experiments (RYU and LONG). Boxplots are expressed as mean  $\pm$  SD. (D) Immunohistochemistry of RYU and LONG at the subrenal capsule of the kidney 7 days after the implantation (n = 3), using antibodies to CDX2, AE1/3, and Vimentin. Scale bar of zoomed sections represents 100  $\mu$ m.

**Additional file6:** Pharmacokinetics-related gene expression in intestinal epithelial cells (A) Heat map of gene expression in RYU (Passages 5 and 12) and LONG. Expression levels were calculated from the results of triplicate biological experiments. (B) Boxplot of representative human intestinal epithelial stem cells and differentiated cell markers. Boxplots are expressed as mean  $\pm$  SD (n = 3 triplicate biological experiments). (C) Expression of the genes for nuclear receptors (VDR, PXR, AHR, and GR). The expression level of adult small intestine whole tissue was set to 1.0. Expression levels were calculated from the results of triplicate biological experiments. Results are expressed as mean  $\pm$  SD (n = 3 triplicate biological experiments). ES-LONG: human ESC-derived mesenchymal stromal cells, ES-RYU: human ESC-derived intestinal epithelial cells, iPS-LONG: human iPSC-derived mesenchymal stromal cells, iPS-RYU: human iPSC-derived intestinal epithelial cells. (D) Inhibition and induction of the cytochrome P450 genes with exposure to Rifampicin (Rif) and Ketoconazole (Ket). Results are expressed as mean  $\pm$  SD (n = 3). The expression level of each gene without any treatment (DMSO) was set to 1.0. Expression levels were calculated from the results of independent (biological) triplicate experiments. (E) 6 $\beta$ -hydroxy testosterone concentration over time in CYP3A4 activity tests. ES-RYU: human ESC-derived intestinal epithelial cells (blue), iPS-RYU: human iPSC-derived intestinal epithelial cells (orange), Caco-2 (gray).

**Additional file7:** Puromycin-based selection of intestinal epithelial cells (A) Phase-contrast photomicrographs of RYU, LONG and human ESCs upon exposure to puromycin. Puromycin (1  $\mu$ g/mL) was added (Day 0). Scale bars: 500  $\mu$ m. (B) Experimental schematic for RYU on LONG. (C) Phase-contrast micrograph and immunocytochemistry of RYU with exposure to puromycin. Immunocytochemistry was performed with antibodies to proteins involved in barrier functions (ECAD, CDH17, ZO-1, Claudin-2, Claudin-7) and CDX2. Nuclei were stained with DAPI. Scale bars: 500 (black) and 50 (yellow)  $\mu$ m. (D) Trans-epithelial electrical resistance measurements for RYU. LONG and Caco-2 cells served as negative and positive controls, respectively. White bars are puromycin-untreated RYU on LONG, and black bars are puromycin-treated RYU on LONG. Results are expressed as mean  $\pm$  SD (n = 3 triplicate biological experiments). Statistical significance was determined using Student's t-test. (E) Lucifer Yellow permeability tests for RYU on LONG. Caco-2 cells served as a control. Black and white bars are treated and non-treated with puromycin, respectively. Results are expressed as mean  $\pm$  SD (n = 3 triplicate biological experiments). Statistical significance was determined using Student's t-test. \* < 0.05, \*\* < 0.01. (F) Lucifer Yellow permeability test was performed for barrier performance. Barrier performance of RYU (Puromycin-treated (+) and non-treated (-)) was altered in culture. Blue line, Puromycin-treated; orange line, Puromycin-untreated. Results are expressed as mean  $\pm$  SD (n = 3 triplicate biological experiments). Statistical significance was determined using Student's t-test; \* < 0.05, \*\* < 0.01. (G) Lucifer yellow concentration over time in lucifer yellow permeability tests 16 and 20 days after confluence. Puromycin-untreated (-, orange), Puromycin-treated (+, blue). (H) Phase-contrast photomicrographs of RYU on LONG (Puromycin-treated (+) and non-treated (-)) 16 and 20 days after confluence. Pre- and

post-Lucifer Yellow permeability test is shown on the left and right panels, respectively. Scale bars: 500  $\mu$ m. (I) Permeability test with Rhodamine 123. The efflux ratio (ER) for Rhodamine 123 was derived from the Papp values associated with basal-to-apical transport (B to A) and apical-to-basal transport (A to B). iPSC-RYU and ESC-RYU on LONG. Analysis was performed in the Puromycin-treated (+) or non-treated (-). ESC-RYU: ESC-derived intestinal epithelial cells, iPSC-RYU: iPSC-derived intestinal epithelial cells. Caco-2 cells served a positive control. Results are expressed as mean  $\pm$  SD ( $n = 3$  triplicate biological experiments). (J) Expression of the genes for transporters (P-gp, BCRP, PEPT1, OATP2B1, MRP2, and MRP3). The expression level of adult small intestine whole tissue was set to 1.0. Expression levels were calculated from the results of independent (biological) triplicate experiments. Black bars are puromycin-untreated, and gray bars are puromycin-treated RYU on LONG. Results are expressed as mean  $\pm$  SD ( $n = 3$ ). ES-RYU: human ESC-derived intestinal epithelial cells, iPSC-RYU: human iPSC-derived intestinal epithelial cells.

**Additional file 8:** Time-lapse image of the proliferation of ESC-derived intestinal epithelial cells on the mesenchymal stromal cells

### Acknowledgements

We would like to express our sincere thanks to K. Miyado and M. Komura for fruitful discussion, to M. Ichinose for providing expert technical assistance, to C. Ketcham for English editing and proofreading, and to E. Suzuki and K. Saito for secretarial work. During the preparation of this work, CJ and AU used DeepL, Grammarly, and ChatGPT for English writing. After using DeepL, Grammarly, and ChatGPT, CJ and AU reviewed and edited the content as needed and take full responsibility for the content of the publication.

### Author contributions

AU and JC designed the experiments. JC, SH, SK, HK, SA and TA performed the experiments. JC, TKaw, SH and SA analyzed data. SH, SA, TKawa, TKiy, HA, and SI contributed to the reagents, tissues and analysis tools. JC, SA, SH, TKim, TKiy, SI and AU discussed the data and manuscript. JC and AU wrote this manuscript. All authors read and approved the final manuscript.

### Funding

This research was supported by AMED; by KAKENHI; by the Grant of National Center for Child Health and Development; by JST, the establishment of university fellowships toward the creation of science technology innovation, Grant Number JPMJFS2102. The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

### Availability of data and materials

The datasets and cells used during the current study are available from the corresponding author on reasonable request.

### Declarations

#### Ethics approval and consent to participate

All experiments involving handling of human cells and tissues were approved by the Institutional Review Board at the National Center for Child Health and Development (2021–178). In compliance with the Declaration of Helsinki, informed consent was obtained from all tissues and cell donors. When the donors were under 18, informed consent was obtained from parents. Human cells in this study were utilized in full compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Ministry of Health, Labor, and Welfare (MHLW), Japan; Ministry of Education, Culture, Sports, Science and Technology (MEXT, Japan) and performed in full compliance with the Ethical Guidelines for Clinical Studies (Ministry of Health, Labor, and Welfare, Japan). The cells were banked after approval of the Institutional Review Board at the National Institute of Biomedical Innovation (May 9, 2006). The derivation and cultivation of human embryonic stem cell (hESC) lines were performed in full compliance with "the Guidelines for Derivation and Distribution of Human Embryonic Stem Cells (Notification of MEXT, No. 156 of August 21, 2009; Notification of MEXT, No. 86 of May 20, 2010) and "the Guidelines for Utilization of Human Embryonic Stem Cells (Notification of MEXT, No. 157 of August 21, 2009; Notification of MEXT, No. 87 of May 20, 2010)". All

procedures of animal experiments were approved by the Institutional Animal Care and Use Committee in National Center for Child Health and Development, based on the basic guidelines for the conduct of animal experiments in implementing agencies under the jurisdiction of the Ministry of Health, Labor and Welfare (Notification of MHLW, No. 0220–1 of February 20, 2015). The Institutional Animal Care and Use Committee of the National Center for Child Health and Development approved the protocols of the animal experiments (approval number: A2003-002-C20-M01, title: Research on regenerative medicine and cell medicine using mesenchymal stem cells, iPSC cells, and ES cells, and on toxicity testing). Animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee of the National Research Institute for Child Health and Development.

### Consent for publication

Not applicable.

### Competing interests

AU is an Associate Editor of the journal, but he was not involved in the peer review process or the decision-making of this article. AU and CJ are co-researchers with Dai Nippon Printing Ltd. AU is a stockholder of iHaes. The other authors declare that there is no conflict of interest regarding the work described herein.

### Author details

<sup>1</sup>Center for Regenerative Medicine, National Center for Child Health and Development Research Institute, 2-10-1 Okura, Setagaya, Tokyo 157-8535, Japan. <sup>2</sup>Department of Advanced Pediatric Medicine, Tohoku University School of Medicine, Sendai, Japan. <sup>3</sup>Division of Pharmacology, National Institute of Health Sciences, Kawasaki, Japan. <sup>4</sup>1st Section, 1st Development Department, Food and Healthcare Business Development Unit, Business Development Division, Research & Business Development Center, Dai Nippon Printing Co., Ltd., Tokyo, Japan. <sup>5</sup>Laboratory of Stem Cell Biology, Department of BioSciences, Kitasato University School of Science, Kanagawa, Japan. <sup>6</sup>Project for Prevention of HPV-Related Cancer, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan. <sup>7</sup>Graduate School of Engineering, Sojo University, Kumamoto, Japan.

Received: 3 September 2023 Accepted: 27 December 2023

Published online: 17 January 2024

### References

- Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther.* 2013;138:103–41.
- International Transporter Consortium, Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, et al. Membrane transporters in drug development. *Nat Rev Drug Discov.* 2010;9:215–36.
- Harwood MD, Achour B, Neuhoff S, Russell MR, Carlson G, Warhurst G, et al. In vitro-in vivo extrapolation scaling factors for intestinal p-glycoprotein and breast cancer resistance protein: part I: a cross-laboratory comparison of transporter-protein abundances and relative expression factors in human intestine and Caco-2 cells. *Drug Metab Dispos.* 2016;44:297–307.
- Sun H, Chow EC, Liu S, Du Y, Pang KS. The Caco-2 cell monolayer: usefulness and limitations. *Expert Opin Drug Metab Toxicol.* 2008;4:395–411.
- Huch M, Bonfanti P, Boj SF, Sato T, Loomans CJM, van de Wetering M, et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. *EMBO J.* 2013;32:2708–21.
- Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature.* 2013;499:481–4.
- Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature.* 2009;459:262–5.
- Huch M, Dorrell C, Boj SF, van Es JH, Li VSW, van de Wetering M, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. *Nature.* 2013;494:247–50.

9. Uchida H, Machida M, Miura T, Kawasaki T, Okazaki T, Sasaki K, et al. A xenogeneic-free system generating functional human gut organoids from pluripotent stem cells. *JCI Insight*. 2017;2: e86492.
10. Davis H, Irshad S, Bansal M, Rafferty H, Boitsova T, Bardella C, et al. Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. *Nat Med*. 2015;21:62–70.
11. Jaeger E, Leedham S, Lewis A, Segditsas S, Becker M, Cuadrado PR, et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. *Nat Genet*. 2012;44:699–703.
12. Farin HF, Van Es JH, Clevers H. Redundant sources of Wnt regulate intestinal stem cells and promote formation of Paneth cells. *Gastroenterology*. 2012;143:1518–29.e7.
13. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. *Science*. 2013;340:1190–4.
14. Lahar N, Lei NY, Wang J, Jabaji Z, Tung SC, Joshi V, et al. Intestinal subepithelial myofibroblasts support in vitro and in vivo growth of human small intestinal epithelium. *PLoS ONE*. 2011;6: e26898.
15. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts II Intestinal subepithelial myofibroblasts. *Am J Physiol*. 1999;277:C183–201.
16. Pinchuk IV, Mifflin RC, Saada JI, Powell DW. Intestinal mesenchymal cells. *Curr Gastroenterol Rep*. 2010;12:310–8.
17. Jacob J-M, Di Carlo SE, Stzepourginski I, Lepelletier A, Ndiaye PD, Varet H, et al. PDGFR $\alpha$ -induced stromal maturation is required to restrain postnatal intestinal epithelial stemness and promote defense mechanisms. *Cell Stem Cell*. 2022;29:856–68.e5.
18. McCarthy N, Manieri E, Storm EE, Saadatpour A, Luoma AM, Kapoor VN, et al. Distinct mesenchymal cell populations generate the essential intestinal BMP signaling gradient. *Cell Stem Cell*. 2020;26:391–402.e5.
19. Akiyama S, Saku N, Miyata S, Ite K, Toyoda M, Kimura T, et al. Drug metabolic activity is a critical cell-intrinsic determinant for selection of hepatocytes during long-term culture. *Stem Cell Res Ther*. 2022;13:104.
20. Nishino K, Arai Y, Takasawa K, Toyoda M, Yamazaki-Inoue M, Sugawara T, et al. Epigenetic-scale comparison of human iPSCs generated by retrovirus, Sendai virus or episomal vectors. *Regen Ther*. 2018;9:71–8.
21. Nishino K, Toyoda M, Yamazaki-Inoue M, Fukawatase Y, Chikazawa E, Sakaguchi H, et al. DNA methylation dynamics in human induced pluripotent stem cells over time. *PLoS Genet*. 2011;7: e1002085.
22. Akutsu H, Machida M, Kanzaki S, Sugawara T, Ohkura T, Nakamura N, et al. Xenogeneic-free defined conditions for derivation and expansion of human embryonic stem cells with mesenchymal stem cells. *Regen Ther*. 2015;1:18–29.
23. Akutsu H, Nasu M, Morinaga S, Motoyama T, Homma N, Machida M, et al. In vivo maturation of human embryonic stem cell-derived teratoma over time. *Regen Ther*. 2016;5:31–9.
24. Wang X, Yamamoto Y, Wilson LH, Zhang T, Howitt BE, Farrow MA, et al. Cloning and variation of ground state intestinal stem cells. *Nature*. 2015;522:173–8.
25. Tsuneishi R, Saku N, Miyata S, Akiyama S, Javaregowda PK, Ite K, et al. Ammonia-based enrichment and long-term propagation of zone I hepatocyte-like cells. *Sci Rep*. 2021;11:1381.
26. Takagi R, Tanuma-Takahashi A, Akiyama S, Kaneko W, Miura C, Yamato M, et al. Laminin-511-derived recombinant fragment and Rho kinase inhibitor Y-27632 facilitate serial cultivation of keratinocytes differentiated from human embryonic stem cells. *Regenerative Therapy*. 2021;18:242–52.
27. Miyata S, Saku N, Akiyama S, Javaregowda PK, Ite K, Takashima N, et al. Puromycin-based purification of cells with high expression of the cytochrome P450 CYP3A4 gene from a patient with drug-induced liver injury (DILI). *Stem Cell Res Ther*. 2022;13:6.
28. Yokomizo R, Fujiki Y, Kishigami H, Kishi H, Kiyono T, Nakayama S, et al. Endometrial regeneration with endometrial epithelium: homologous orchestration with endometrial stroma as a feeder. *Stem Cell Res Ther*. 2021;12:130.
29. McCarthy N, Kraczy J, Shivdasani RA. Cellular and molecular architecture of the intestinal stem cell niche. *Nat Cell Biol*. 2020;22:1033–41.
30. Gregorieff A, Pinto D, Begthel H, Destree O, Kielman M, Clevers H. Expression pattern of Wnt signaling components in the adult intestine. *Gastroenterology*. 2005;129:626–38.
31. Gracz AD, Fuller MK, Wang F, Li L, Stelzner M, Dunn JCY, et al. Brief report: CD24 and CD44 mark human intestinal epithelial cell populations with characteristics of active and facultative stem cells. *Stem Cells*. 2013;31:2024–30.
32. Xie G, Peng Z, Liang J, Larabee SM, Drachenberg CB, Yfantis H, et al. Zinc finger protein 277 is an intestinal transit-amplifying cell marker and colon cancer oncogene. *JCI Insight*. 2022. <https://doi.org/10.1172/jci.insight.150894>.
33. de Lau W, Barker N, Low TY, Koo B-K, Li VSW, Teunissen H, et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signaling. *Nature*. 2011;476:293–7.
34. Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner DL. Human cancer growth and therapy in immunodeficient mouse models. *Cold Spring Harb Protoc*. 2014;2014:694–708.
35. Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? *Clin Pharmacokinet*. 2002;41:235–53.
36. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. THE HUMAN INTESTINAL CYTOCHROME P450 "PIE." *Drug Metab Dispos*. 2006;34:880–6.
37. Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. *Drug Metab Dispos*. 2006;34:1734–41.
38. Wang J, Williams ET, Bourgea J, Wong YN, Patten CJ. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2. *Drug Metab Dispos*. 2011;39:1329–33.
39. Imai T, Imoto M, Sakamoto H, Hashimoto M. Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. *Drug Metab Dispos*. 2005;33:1185–90.
40. Glaeser H, Drescher S, Eichelbaum M, Fromm MF. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. *Br J Clin Pharmacol*. 2005;59:199–206.
41. Theodoropoulos C, Demers C, Delvin E, Ménard D, Gascon-Barré M. Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. *Clin Endocrinol*. 2003;58:489–99.
42. Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. *Expert Rev Clin Pharmacol*. 2012;5:569–85.
43. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. *J Clin*. 2007. <https://doi.org/10.1177/0091270007299930>.
44. Janssen AWF, Duivenvoorde LPM, Rijkers D, Nijssen R, Peijnenburg AACM, van der Zande M, et al. Cytochrome P450 expression, induction and activity in human induced pluripotent stem cell-derived intestinal organoids and comparison with primary human intestinal epithelial cells and Caco-2 cells. *Arch Toxicol*. 2021;95:907–22.
45. Kondo A, Kaestner KH. Emerging diverse roles of telocytes. *Development*. 2019. <https://doi.org/10.1242/dev.175018>.
46. Shoshkes-Carmel M, Wang YJ, Wangenstein KJ, Tóth B, Kondo A, Massasa EE, et al. Author correction: subepithelial telocytes are an important source of Wnts that supports intestinal crypts. *Nature*. 2018;560:E29.
47. Greicius G, Kabiri Z, Sigmundsson K, Liang C, Bunte R, Singh MK, et al. PDGFR $\alpha$ + pericytial stromal cells are the critical source of Wnts and RSPQ3 for murine intestinal stem cells in vivo. *Proc Natl Acad Sci U S A*. 2018;115:E3173–81.
48. Sailaja BS, He XC, Li L. The regulatory niche of intestinal stem cells. *J Physiol*. 2016;594:4827–36.
49. Qi Z, Li Y, Zhao B, Xu C, Liu Y, Li H, et al. BMP restricts stemness of intestinal Lgr5+ stem cells by directly suppressing their signature genes. *Nat Commun*. 2017;8:13824.
50. Yan KS, Janda CY, Chang J, Zheng GXY, Larkin KA, Luca VC, et al. Non-equivalence of Wnt and R-spondin ligands during Lgr5+ intestinal stem-cell self-renewal. *Nature*. 2017;545:238–42.
51. Nusse YM, Savage AK, Marangoni P, Rosendahl-Huber AKM, Landman TA, de Sauvage FJ, et al. Parasitic helminths induce fetal-like reversion in the intestinal stem cell niche. *Nature*. 2018;559:109–13.
52. Lock JY, Carlson TL, Carrier RL. Mucus models to evaluate the diffusion of drugs and particles. *Adv Drug Deliv Rev*. 2018;124:34–49.
53. Negoro R, Takayama K, Nagamoto Y, Sakurai F, Tachibana M, Mizuguchi H. Modeling of drug-mediated CYP3A4 induction by using human

iPS cell-derived enterocyte-like cells. *Biochem Biophys Res Commun.* 2016;472:631–6.

54. Fujino A, Fuchimoto Y, Baba Y, Isogawa N, Iwata T, Arai K, et al. First-in-human autologous oral mucosal epithelial sheet transplantation to prevent anastomotic re-stenosis in congenital esophageal atresia. *Stem Cell Res Ther.* 2022;13:35.
55. Watanabe S, Kobayashi S, Ogasawara N, Okamoto R, Nakamura T, Watanabe M, et al. Transplantation of intestinal organoids into a mouse model of colitis. *Nat Protoc.* 2022;17:649–71.
56. Anderson P, Souza-Moreira L, Morell M, Caro M, O'Valle F, Gonzalez-Rey E, et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. *Gut.* 2013;62:1131–41.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

